A metabolite panel in combination with CA19-9, tissue inhibitor of metalloproteinase 1, and LRG1 exhibited substantially improved performance in the detection of early-stage pancreatic ductal adenocarcinoma (Fahrmann et al., 2019). The gene discussed is LRG1; the disease is pancreatic ductal adenocarcinoma.